ARK Invest's position in ARCT, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 3,153,681 | $26.6M | 1.35% | #23 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-30 | ARKG | Buy | Added | 64,483 | $711K |
| 2026-10-29 | ARKG | Buy | Added | 19,316 | $235K |
| 2026-10-27 | ARKG | Buy | Added | 12,237 | $137K |
| 2026-10-26 | ARKG | Buy | Added | 23,250 | $230K |
| 2026-04-09 | ARKG | Buy | Added | 3,447 | $28K |
| 2026-04-08 | ARKG | Buy | Added | 4,787 | $41K |
| 2026-04-02 | ARKG | Buy | Added | 636 | $5K |
| 2026-04-01 | ARKG | Buy | Added | 7,182 | $56K |
| 2026-03-30 | ARKG | Buy | Added | 8,855 | $61K |
| 2026-03-27 | ARKG | Buy | Added | 48,659 | $329K |
| 2026-03-24 | ARKG | Buy | Added | 4,525 | $30K |
| 2026-03-20 | ARKG | Buy | Added | 22,773 | $151K |
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development;…
See ARCT's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open ARCT on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.